{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:16:08Z","timestamp":1790046968900,"version":"4.0.1"},"reference-count":101,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.3109\/10428190903452834","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T11:34:47Z","timestamp":1276860887000},"page":"188-198","source":"Crossref","is-referenced-by-count":18,"title":["Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1080","volume":"51","author":[{"given":"Wendy","family":"Stock","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Hematology and Oncology, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,12,9]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.118"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70198-2"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4666"},{"key":"e_1_3_2_5_1","first-page":"4674","article-title":"Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate","volume":"9","author":"Pfeifer H","year":"2003","unstructured":"Pfeifer H, Wassmann B, Hofmann WK, et al Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9:4674\u20134681.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703899"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403886"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3785"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.685.685","article-title":"Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH+ALL) [abstract]","volume":"104","author":"Ottmann OG","year":"2004","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, et al Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH+ALL) [abstract]. Blood 2004;104(Suppl.):(Abstract 685).","journal-title":"Blood"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.1830.1830","article-title":"Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]","volume":"106","author":"Thomas DA","year":"2005","unstructured":"Thomas DA, Faderl S, Cortes J, et al Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood 2005;106(Suppl.):(Abstract 1830).","journal-title":"Blood"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.12.1.165"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00097-4"},{"key":"e_1_3_2_19_1","first-page":"533","volume-title":"American Society of Clinical Oncology Educational Book","author":"Hoelzer D","year":"2002","unstructured":"Hoelzer D, Gokbuget N. Treatment of elderly patients with acute lymphoblastic leukemia [abstract]. In: Perry MC, editor. American Society of Clinical Oncology Educational Book. Baltimore, MD: Lippincott Williams and Wilkins; 2002. pp 533\u2013539."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057984"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70190-8"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199380"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.3067.3067"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.4.1410"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401589"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1572"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705464"},{"key":"e_1_3_2_30_1","article-title":"Autologous BMT\/PBSCT in 40 patients with bcr-abl positive acute lymphoblastic leukemia: long-term follow-up of a GMALL study [abstract]","author":"Martin H","year":"2001","unstructured":"Martin H, Atta J, Klein SA, et al Autologous BMT\/PBSCT in 40 patients with bcr-abl positive acute lymphoblastic leukemia: long-term follow-up of a GMALL study [abstract]. Hematol J 2001;I:Abstract 187.","journal-title":"Hematol J"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"issue":"8","key":"e_1_3_2_35_1","article-title":"A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]","volume":"25","author":"Larson R","year":"2007","unstructured":"Larson R, Ottmann O, Kantarjian H, et al A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol 2007;25(Suppl. 8):(Abstract 7040).","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404320"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22631"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2739.2739","article-title":"Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201 [abstract]","volume":"104","author":"Vignetti M","year":"2004","unstructured":"Vignetti M, Fazi P, Meloni G, et al Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201 [abstract]. Blood 2004;104(Suppl.):(Abstract 2739).","journal-title":"Blood"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.8.8","article-title":"Does imatinib change the outcome in Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII\/ECOG2993 study [abstract]","volume":"110","author":"Fielding AK","year":"2007","unstructured":"Fielding AK, Richards SM, Lazarus HM, et al Does imatinib change the outcome in Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII\/ECOG2993 study [abstract]. Blood 2007;110(Suppl.):(Abstract 8).","journal-title":"Blood"},{"key":"e_1_3_2_40_1","article-title":"Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphocytic leukemia (ALL) [abstract]","volume":"112","author":"Thomas DA","year":"2008","unstructured":"Thomas DA, Kantarjian HM, Cortes J, et al Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood 2008;112(Suppl.):(Abstract 2931).","journal-title":"Blood"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.4.4","article-title":"Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031 [abstract]","volume":"110","author":"Schultz KR","year":"2007","unstructured":"Schultz KR, Bowman P, Slayton W, et al Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031 [abstract]. Blood 2007;110(Suppl.):(Abstract 4).","journal-title":"Blood"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402304"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03988.x"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01605.x"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Radich J","year":"1997","unstructured":"Radich J, Gehly G, Lee A, et al Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997;89:2602\u20132609.","journal-title":"Blood"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)70011-1"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1746"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07377.x"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001625755"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.531"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-052373"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403257"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.1070"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4276"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4687"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403426"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402290200"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606509103"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf562"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605902200"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020519"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1127"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.11.3884-3896.2003"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403416"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.10.8.4365-4369.1990"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.9.2.329"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206008"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600001103"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409770102"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822"},{"key":"e_1_3_2_80_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2926.2926","article-title":"Dasatinib 140\u2009mg once daily (QD) has equivalent efficacy and improved safety compared with 70\u2009mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035 [abstract]","volume":"112","author":"Larson RA","year":"2008","unstructured":"Larson RA, Ottmann OG, Shah NP, et al Dasatinib 140\u2009mg once daily (QD) has equivalent efficacy and improved safety compared with 70\u2009mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035 [abstract]. Blood 2008;112(Suppl.):(Abstract 2926).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_2_81_1","article-title":"Dasatinib is an effective treatment of central nervous system Ph-positive leukemia [abstract]","volume":"92","author":"Koskenvesa P","year":"2007","unstructured":"Koskenvesa P, Rimpilainen J, Lundan T, et al Dasatinib is an effective treatment of central nervous system Ph-positive leukemia [abstract]. Haematologica 2007;92(Suppl. 2):(Abstract 0315).","journal-title":"Haematologica"},{"key":"e_1_3_2_82_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1988.1988","article-title":"BMS-354825, a dual SRC\/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth [abstract]","volume":"104","author":"Wild R","year":"2004","unstructured":"Wild R, Castaneda S, Flefleh C, et al BMS-354825, a dual SRC\/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth [abstract]. Blood 2004;104(Suppl.):(Abstract 1988).","journal-title":"Blood"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045260"},{"key":"e_1_3_2_84_1","article-title":"Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study [abstract]","volume":"112","author":"Foa R","year":"2008","unstructured":"Foa R, Vitale A, Guarini A, et al Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study [abstract]. Blood 2008;112(Suppl.):(Abstract 305).","journal-title":"Blood"},{"key":"e_1_3_2_85_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2921.2921","article-title":"Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]","volume":"112","author":"Ravandi F","year":"2008","unstructured":"Ravandi F, Thomas D, Kantarjian H, et al Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. Blood 2008;112(Suppl.):(Abstract 2921).","journal-title":"Blood"},{"key":"e_1_3_2_86_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2920.2920","article-title":"Dasatinib (Sprycel\u00ae) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: results of the first 22 patients included in the EWALL-Ph-01 trial (on behalf of the European Working Group on Adult ALL [EWALL]) [abstract]","volume":"112","author":"Rousselot P","year":"2008","unstructured":"Rousselot P, Cayuela J-M, Recher C, et al Dasatinib (Sprycel\u00ae) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: results of the first 22 patients included in the EWALL-Ph-01 trial (on behalf of the European Working Group on Adult ALL [EWALL]) [abstract]. Blood 2008;112(Suppl.):(Abstract 2920).","journal-title":"Blood"},{"key":"e_1_3_2_87_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2919.2919","article-title":"Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB) [abstract]","volume":"112","author":"Jabbour E","year":"2008","unstructured":"Jabbour E, O'Brien S, Thomas DA, et al Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB) [abstract]. Blood 2008;112(Suppl.):(Abstract 2919).","journal-title":"Blood"},{"key":"e_1_3_2_88_1","article-title":"AMN107: efficacy of the selective Bcr-Abl tyrosine kinase inhibitor in a murine model of chronic myelogenous leukemia [abstract]","volume":"47","author":"Jensen MR","year":"2006","unstructured":"Jensen MR, Bruggen J, Dilea C, Mestan J, Manley PW. AMN107: efficacy of the selective Bcr-Abl tyrosine kinase inhibitor in a murine model of chronic myelogenous leukemia [abstract]. Proc Am Assoc Cancer Res 2006;47:(Abstract 261).","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_2_91_1","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas JM","year":"2003","unstructured":"Golas JM, Arndt K, Etienne C, et al SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375\u2013381.","journal-title":"Cancer Res"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2209"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.01.006"},{"key":"e_1_3_2_94_1","article-title":"Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]","volume":"112","author":"Gambacorti-Passarini C","year":"2008","unstructured":"Gambacorti-Passarini C, Pogliani EM, Baccarani M, et al Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 2008;112(Suppl.):(Abstract 1101).","journal-title":"Blood"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504952102"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-025049"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1003"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2788"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094508"},{"key":"e_1_3_2_100_1","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli R","year":"2003","unstructured":"Nimmanapalli R, Fuino L, Bali P, et al Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126\u20135135.","journal-title":"Cancer Res"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06866"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0154"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428190903452834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:37:06Z","timestamp":1770381426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428190903452834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,9]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.3109\/10428190903452834"],"URL":"https:\/\/doi.org\/10.3109\/10428190903452834","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,9]]}}}